Search

everythinglearnresearchcommunity

for

Search:↓

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

Finasteride breaks down into new compounds under acidic conditions.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

Overexpressing SSAT enzyme reduces prostate tumor growth in mice.

A new topical treatment for hair loss shows promise by targeting androgen receptors.

Minoxidil breakdown varies by enzymes, affecting hair loss treatment effectiveness.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Testosterone and its metabolites affect brain functions and could help treat neurological disorders.

Balancing lipophilicity and solubility is key for effective and safe ketorolac prodrugs.

People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.

Phytochemicals may offer safer alternatives to synthetic drugs for prostate cancer treatment.

The enzyme that changes testosterone to a stronger form is mostly found in the part of the hair follicle called the dermal papilla.

5α-reductase-2 deficiency causes ambiguous genitalia at birth and affects male sexual development, but individuals often develop male characteristics at puberty.

The study identified a key protein involved in producing underarm odor and found ways to inhibit it.

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

Altering the keratin 17 gene in mice hair follicles caused temporary hair issues, but changes were minimal and short-lived.

Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.

New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.

5α-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT levels.

A new gene mutation causes hereditary coproporphyria with reduced enzyme activity.

5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.

ODC transgenic mice can model human hair loss with skin lesions.

Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.

Liver enzyme helps minoxidil work better for blood vessel relaxation.

Urtica dioica extract may help treat androgenic skin diseases by reducing a specific gene's activity.

Ornithine decarboxylase is crucial for hair growth and follicle development.

Steroidogenic isoenzymes may help improve treatments for common hair loss.

4-azasteroids, including finasteride, can inhibit 5α-reductase, helping treat conditions like enlarged prostate and hair loss.